

## **Amendments to the Claims**

The following listing of claims replaces all previous listings or versions thereof:

### **Listing of the Claims:**

1. (currently amended) A method of reducing or overcoming acquired or inherent cellular resistance to cytotoxic or anti-neoplastic agents, comprising the step of co-administering systemically to a patient in need thereof an effective amount of said agent together with hyaluronan, wherein said agent is more cytotoxically or anti-neoplastically effective than compared to the same amount of agent alone, and wherein said hyaluronan has a molecular weight greater than or equal to about 750,000 Daltons.
2. (currently amended) A method according to claim 1, wherein the agent is selected from the group consisting of methotrexate, paclitaxel (~~taxol~~)(TAXOL), 5-fluorouracil and cyclophosphamide or combinations thereof.
3. (original) A method according to claim 2, wherein said agent is combined with hyaluronan such that the agent is entrained and/or bound by said hyaluronan.
4. (original) A method according to claim 3, wherein said combined agent and hyaluronan is capable of binding to receptors on the resistant cell.
5. (original) A method according to claim 3, wherein said combined agent and hyaluronan is capable of entering a resistant cell via bulk endocytosis, wherein said agent is delivered into the cell, thereby allowing it to become therapeutically active.
6. (original) A method according to claim 1, wherein the acquired or inherent cellular resistance is associated with a drug-resistant disease.
7. (original) A method according to claim 6, wherein the drug-resistant disease is a drug-resistant cancer.
8. (currently amended) A method for the reduction of gastrointestinal toxicity of a drug, comprising the step of co-administering systemically to a patient in need thereof an

effective amount of said [[agent]]drug together with hyaluronan , wherein said [[agent]]drug has reduced gastrointestinal toxicity when compared to the same amount of the [[agent]]drug alone, and wherein said hyaluronan has a molecular weight greater than or equal to about 750,000 Daltons.

9. (currently amended) A pharmaceutical composition for reducing or overcoming acquired or inherent cellular resistance to cytotoxic or anti-neoplastic agents comprising:  
hyaluronan, having a molecular weight ~~greater than 700,000 Daltons~~greater than or equal to about 750,000 Daltons, and  
a cytotoxic or anti-neoplastic agent, wherein said composition is administered systemically to a patient in need thereof and is more cytotoxically or anti-neoplastically effective than compared to said agent alone, ~~with the proviso that when the agent is paclitaxel the molecular weight of hyaluronan is greater than 750,000 Daltons.~~